FOSTER CITY, Calif., March 21, 2017 /PRNewswire/ -- SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of a $60 million Series B...
March 21, 2017 at 04:22PM
http://ift.tt/2mojwdO
from
http://ift.tt/2mojwdO
No comments:
Post a Comment